ANI Pharmaceuticals Inc
NASDAQ:ANIP

Watchlist Manager
ANI Pharmaceuticals Inc Logo
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Watchlist
Price: 54.16 USD -0.4%
Market Cap: 1.1B USD
Have any thoughts about
ANI Pharmaceuticals Inc?
Write Note

Gross Margin
ANI Pharmaceuticals Inc

60.7%
Current
58%
Average
48.5%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
60.7%
=
Gross Profit
420.4m
/
Revenue
692.9m

Gross Margin Across Competitors

Country US
Market Cap 1.1B USD
Gross Margin
61%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 747.7B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.8T DKK
Gross Margin
85%
Country US
Market Cap 342.5B USD
Gross Margin
69%
Country US
Market Cap 252.8B USD
Gross Margin
77%
Country CH
Market Cap 216.8B CHF
Gross Margin
73%
Country UK
Market Cap 169.5B GBP
Gross Margin
82%
Country CH
Market Cap 180B CHF
Gross Margin
75%
Country US
Market Cap 152.2B USD
Gross Margin
71%
No Stocks Found

ANI Pharmaceuticals Inc
Glance View

Market Cap
1.1B USD
Industry
Pharmaceuticals

ANI Pharmaceuticals Inc. operates at the heart of the pharmaceutical industry with a focused strategy that blends generics with niche high-value medications. Born in the realm of specialty pharmaceuticals, the company has crafted a business model that leverages both organic growth and strategic acquisitions. This dual approach helps the company to broaden its product offerings and maintain a robust pipeline. By targeting niche markets often overlooked by larger pharmaceutical giants, ANI maximizes its opportunities in areas with less competitive congestion. Central to its operations is the manufacturing and marketing of generic prescription products that are not only critically required but also pose less risk of commoditization due to their complexity, regulatory hurdles, or limited manufacturing capabilities. Revenue generation for ANI is a sophisticated blend of manufacturing, marketing, and brand positioning. The company's infrastructure supports integrated product development, regulatory approval, and scalable manufacturing processes. This allows them to efficiently bring to market a diverse portfolio of more than a hundred products across therapeutic areas. Additionally, ANI taps into revenue streams by producing legacy branded drugs often acquired from larger players looking to offload non-core assets. These legacy products, while sometimes in smaller volumes, benefit from loyal prescriber bases and established market presence, providing a steady income for the company. In essence, ANI Pharmaceuticals thrives on navigating the intricacies of the pharmaceutical supply chain, seizing opportunities in underexplored niches and refocusing the potential of undervalued brands.

ANIP Intrinsic Value
93.06 USD
Undervaluation 42%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
60.7%
=
Gross Profit
420.4m
/
Revenue
692.9m
What is the Gross Margin of ANI Pharmaceuticals Inc?

Based on ANI Pharmaceuticals Inc's most recent financial statements, the company has Gross Margin of 60.7%.